Product Description
Mechanisms of Action: KIF Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Multiple Myeloma
Phase 2: Multiple Myeloma|Leukemia, Plasma Cell|Myelodysplastic Syndrome|Acute Myeloid Leukemia
Phase 1: Multiple Myeloma|Leukemia, Plasma Cell|Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
POMDEFIL | P2 |
Terminated |
Multiple Myeloma |
2020-03-23 |
|
NCI-2011-01120 | P1 |
Completed |
Multiple Myeloma|Leukemia, Plasma Cell |
2019-05-16 |
|
POMDEFIL | P2 |
Completed |
Multiple Myeloma |
2018-02-01 |
|
Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma | P2 |
Completed |
Multiple Myeloma |
2017-09-12 |